Xoft Inc.

Xoft Inc. develops advanced cancer treatment technologies, offering the Elekta Xoft Axxent Electronic Brachytherapy System, which provides targeted radiation therapy options for various cancers, enhancing treatment accessibility and effectiveness. Founded in 1998 in Sunnyvale, California, Xoft Inc. specializes in electronic brachytherapy for cancer treatment.

In December 2010, Xoft was acquired by iCAD for USD 73 mn. The company has engaged in 8 deals to date, focusing on innovative solutions for oncology. Elekta Xoft specializes in advanced cancer treatment technology, primarily through its flagship product, the Elekta Xoft Axxent Electronic Brachytherapy (eBx) System. This system utilizes a 50 kV miniaturized X-ray source to deliver low-energy, high dose rate localized radiation therapy, allowing for effective treatment of early-stage breast cancer, non-melanoma skin cancer (NMSC), and gynecological cancers.

The Elekta Xoft system is designed for versatility and ease of use, requiring no specialized bunkers or shielding, making it accessible across various clinical settings—from outpatient consultation rooms to operating theatres. The company's client base includes cancer treatment centers and healthcare providers looking to implement cost-effective, flexible radiation therapy solutions. Elekta Xoft products are primarily marketed in North America, Europe, and select Asia-Pacific regions, catering to a diverse range of healthcare facilities. Elekta Xoft generates revenue through the sale of its eBx systems, ancillary equipment, and ongoing support services.

The typical transaction structure involves direct sales to healthcare providers and treatment centers, supporting B2B relationships. The company may also offer subscription-based models for software and clinical training resources to ensure optimal use and integration of its technology in clinical workflows. Pricing plans for the Elekta Xoft system and related services are structured to accommodate the varying needs of healthcare institutions, facilitating a streamlined purchasing process. Revenue is derived not only from initial system sales but also from continued partnerships offering training, maintenance, and technical support, ensuring long-term client engagement and satisfaction.

Xoft Inc. plans to leverage recent funding to enhance its product line and expand into new markets. The acquisition by iCAD is expected to accelerate the development of upcoming products aimed at improving cancer treatment outcomes. Additionally, Xoft intends to target expansion in Europe and select Asia-Pacific regions by 2023 to reach more healthcare providers.

The recent acquisition, finalized in December 2010 for USD 73 mn, will support these initiatives by integrating Xoft's technology with iCAD's distribution network.